The US Food and Drug Administration's latest Regulatory Agenda includes the planned publication by May 2020 of a notice of proposed rulemaking to allow firms to submit OTC new drug applications that incorporate extra-label information to help guide consumers' self-selection.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?